Key result
Statins reduce MI and CHD death by ~1% for each percent decrease in non-HDL-C.
Why the study?
Non-HDL-C is the second lipid target of therapy after LDL-C, but the relationship between non-HDL-C lowering and CHD risk reduction across various lipid-modifying therapies needed to be determined.
Does non-HDL-C reduction with lipid-modifying therapies reduce the risk of nonfatal myocardial infarction and CHD death?
Comparison
Lipid-modifying therapies vs placebo or active control
Design
Bayesian random-effects meta-analysis of randomized controlled trials
Authors
Loading...
This meta-analysis demonstrates an approximately 1:1 relationship between the percentage of non-HDL-C lowering and the reduction in CHD risk across various lipid-modifying monotherapies, supporting non-HDL-C as a key therapeutic target.
Meta-Analysis (n=132,021)
Does non-HDL-C reduction with lipid-modifying therapies reduce the risk of nonfatal myocardial infarction and CHD death?
Relative Risk: 0.99 (95% CI 0.98–1)
This meta-analysis demonstrates an approximately 1:1 relationship between the percentage of non-HDL-C lowering and the reduction in CHD risk across various lipid-modifying monotherapies, supporting non-HDL-C as a key therapeutic target.
Robinson et al. (2009) conducted a meta-analysis in Coronary heart disease (n=132,021). Non-HDL-C reduction (lipid-modifying therapies) vs. Placebo or active control was evaluated on Nonfatal myocardial infarction and CHD death (RR 0.99, 95% CI 0.98-1.00). Each 1% decrease in non-HDL-C with statins resulted in a relative risk of 0.99 (95% CI 0.98-1.00) for nonfatal MI and CHD death, with most monotherapies showing a 1:1 relationship.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: